BUFFALO GROVE, Ill. and ROME, June 23, 2015 (GLOBE NEWSWIRE) -- RestorGenex Corporation (OTC:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, announced that Claudio Festuccia, Department of Clinical Sciences and Applied Biotechnology, Università degli Studi dell'Aquila, presented data on June 22, 2015 at the XXVth National Congress of the Italian Society of Uro-Oncology, (SIUrO) in Rome, Italy. In vitro and in vivo data on the use of RES-529 in a prostate cancer cell model was the focus of his oral presentation titled: "RES-529, A Dual TORC1/TORC2 Inhibitor, Potentiates the In Vitro and In Vivo Efficacy of Hormone Manipulations in the 22RV1 Prostate Cancer Cell Model."
"Dr. Festuccia has studied TORC1/TORC2 inhibition extensively in various cancer models. His work on RES-529 has provided RestorGenex with key clinical data that has been integral to our research and development planning," stated Mark Weinberg, MD, MBA, senior vice president of clinical development for RestorGenex. "The most recent data established the role of TORC2 as a promising target for prostate cancer and demonstrated that RES-529 in combination with hormonal therapy has potential as a therapeutic approach. This data builds upon Dr. Festuccia's previously published work demonstrating radiosensitizing effects of TORC1/TORC2 inhibition with RES-529 as well as synergistic effects of the compound in combination chemotherapy."
Professor Claudio Festuccia stated, "Our study evaluated RES-529, a dual TORC1/TORC2 inhibitor, in comparison with RAD001, a Rapamycin analog and TORC1 inhibitor. These agents were studied in combination with androgen deprivation and androgen receptor inhibition. We tested the combination effects with a 5 alpha-reductase inhibitor (Finasteride or Dutasteride), a 17 alpha-hydroxylase inhibitor (Abiraterone) and an androgen receptor blocker (Bicalutamide). We observed that RES-529 was able to synergize with hormone manipulations in 22rv1 tumor models. Superior effects were seen with RES-529 compared with RAD001, suggesting the importance of TORC2 inhibition. We were pleased to present our findings to our distinguished peers and look forward to our next set of experiments where we will evaluate TORC1/TORC2 expression in clinical samples from men with prostate cancer who were treated with hormone therapy."
Stephen M. Simes, chief executive officer of RestorGenex added, "The breadth of the effects of RES-529 in combination with radiotherapy, chemotherapy, and now hormone therapy for prostate cancer provides rationale for combination therapeutic approach. Dr. Festuccia's most recent work suggests that this mechanism could be a promising treatment for hormone sensitive and hormone refractory prostate cancer. We are grateful to Professor Festuccia and his team for their outstanding research."
About RestorGenex Corporation
RestorGenex is a specialty biopharmaceutical company focused on developing a portfolio of first-in-class therapeutic products to treat diseases across the ophthalmologic, oncologic and dermatologic space. RestorGenex's lead product is a novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in pre-clinical development for glioblastoma multiforme. The current pipeline also includes a "soft" anti-androgen compound for the treatment of acne vulgaris. RestorGenex's novel inhibition of the PI3K pathway and unique targeting of the androgen receptor show promise in a number of additional diseases, which the Company is evaluating for the purpose of creating safe and effective treatments and innovative therapies. For additional information please see: www.restorgenex.com.
Forward Looking Statements
Certain statements in this release are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about potential benefits of RES-529 and other statements that are not historical in nature, particularly those that utilize terminology such as "will," "potential," "look forward," "could," "plans," "anticipates," "expects," "may," "future," "continue," "show promise," other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Risks and uncertainties may cause RestorGenex's actual results to be materially different than those expressed in or implied by such forward-looking statements. Particular risks and uncertainties include, among others, uncertainties involved in clinical testing, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance, RestorGenex's ability to license out its existing products and technologies and license in additional products and technologies and the terms of such licenses; and other risks and uncertainties described in RestorGenex's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K for the fiscal year ended December 31, 2014 and subsequent quarterly report on Form 10-Q for the fiscal quarter ended March 31, 2015. All forward-looking statements in this release speak only as of the date of this release and are based on RestorGenex's current beliefs and expectations. RestorGenex undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.